Background em BCR-ABL /em kinase area (KD) mutation may be the main mechanism adding to suboptimal response to tyrosine kinase inhibitors (TKI) in em BCR-ABL /em -positive chronic myeloid leukemia (CML) individuals. characterized by considerable proliferation and development of myeloid cells at differing phases of maturation and differentiation [1]. The sign of CML may be… Continue reading Background em BCR-ABL /em kinase area (KD) mutation may be the